Navigation Links
Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP
Date:1/29/2012

vely work with the European Commission and the EMA to find the best process going forward, not only for Glybera but also for further advanced therapies on their way to patients," said Jörn Aldag, CEO of AMT. "While gaining clarity for the process involving Glybera, we will continue to implement our revised business strategy revealed following the last CHMP decision. This involves moving forward in partnering discussions for several of our gene therapy products, including hemophilia B and GDNF."

AMT's current business plan, organizational structure and financing have been developed on the basis of the current CHMP opinion for Glybera's non-approval. It involved a reduction of its workforce by about 50%. In the event that Glybera could be commercialized in Europe, the Company will evaluate how the opportunity arising from passing this important milestone could be realized most efficiently.

About Glybera®

AMT has developed Glybera as a treatment for patients with the genetic disorder lipoprotein lipase deficiency. LPLD is an orphan disease for which no treatment exists today. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL protein in patients. This protein is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. Excess chylomicrons result in recurrent and severe acute inflammation of the pancreas, called pancreatitis, the most debilitating and life-threatening clinical complication of LPLD. Glybera has orphan drug status in the EU and US.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. In addition to Glybera, AMT has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute interm
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
2. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
3. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
4. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
5. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
6. MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support
7. Molecular Imaging, Inc. Enters Relationship with Dana-Farber Cancer Institute to Expand Luciferase-reporter Cancer Cell Lines for Preclinical in vivo Imaging
8. Quest Diagnostics Launches Simplexa™ Dengue Test in Brazil, First Commercial Molecular Test Approved for Nations Public and Private Health Testing
9. Roche Diagnostics, Cedars-Sinai Medical Center Enter Strategic Alliance for Center to Operate as a Roche Molecular Center of Excellence
10. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
11. GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... , Oct. 18, 2014  In a ... Campaign (HRC), the nation,s largest lesbian, gay, bisexual ... the use of Truvada for Pre-Exposure Prophylaxis (PrEP). ... used to prevent the spread of a disease ... only brand name anti-HIV drug combination currently approved ...
(Date:10/17/2014)... THOUSAND OAKS, Calif. , Oct. 17, 2014 /PRNewswire/ ... appointment of R. Sanders Williams , M.D., president ... L. Mahley Distinguished Professor.  "We are ... the Amgen Board," said Robert A. Bradway , ... deep and distinguished experience in academic medicine and his ...
(Date:10/17/2014)... , October 17, 2014 ... report "Optical Imaging Market by Technique (Optical Coherence ... Imaging software) & by Application (Ophthalmology, Neurology, Oncology, Cardiology) ... MarketsandMarkets, this report studies the Optical Imaging market ... market was valued at $917.1 million in ...
Breaking Medicine Technology:HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4
... DIEGO , May 7 Patients ... maintained clinical improvement at two years, according to ... presented today as a late-breaking clinical trial at ... 33rd Annual Scientific Sessions. The prospective, single-arm study ...
... Speedway Children,s Charities and the National Rifle Association are partnering ... to more than 70 underserved children and adults throughout the Carolinas on ... Charlotte Motor Speedway.  Members of the media are invited to attend the press ... 11:00am in the "Victory Circle." , ...
Cached Medicine Technology:Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 3The Gift of Hearing Will be Delivered Free to Over 75 Beneficiaries, as Speedway Children's Charities and the Starkey Hearing Foundation Host 'Get in Gear to Help Children Hear' 2
(Date:10/20/2014)... October 20, 2014 Principle Business Enterprises, ... pride in manufacturing top-of-the-line absorbent products. The company ... its most popular brand, Tranquility® Premium Protection absorbent products. ... new website, gave its packaging a new look, and ... brand message to the public. , The new website, ...
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live ... the world, it’s a reality. And while new shoes are ... to walk barefoot on rocky terrain or sewage-lined streets just ... friends. , Buckner International's Shoes for Orphan Souls ... October to encourage support for Air1 and while also providing ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... and is performed without anesthesia , , WEDNESDAY, Oct. 3 ... of an innovative form of colonoscopy that relies on ... , When it comes to detecting polyps that ... as effective as the traditional approach of using a ...
... It cuts rates of hospitalizations and deaths, study finds, , , WEDNESDAY, ... an annual flu shot will reduce the risk you,ll be hospitalized ... flu-related death by 48 percent. , That,s the conclusion of new ... England Journal of Medicine . , "This is a bad disease ...
... Calif., Oct. 3 Abaxis, Inc.,(Nasdaq: ABAX ... analysis systems, announced today the launch of the ... the Piccolo xpress(TM) point of,care analyzer. The ... imaging and,radiology centers in the United States to ...
... Acceptance of Umbilical Cord Blood Stem Cells as a Curative ... ... Inc. has been named,to Deloitte,s prestigious Technology Fast 50 Program for ... life sciences companies in the area by Deloitte & Touche USA ...
... CHICAGO, Oct. 3 President Bush,s veto today,of ... for millions of,children from families with low incomes ... dental health, says Oral Health America, a national,advocacy ... ten million children eligible for coverage through a,bipartisan, ...
... regarded as a barometer of a populations general health ... rate in 2006 was 5.9 infant deaths for every 1,000 ... made major progress in reducing infant deaths since the early ... but the decline has leveled off in recent years. The ...
Cached Medicine News:Health News:'Virtual' Colonoscopy an Effective Option: Study 2Health News:'Virtual' Colonoscopy an Effective Option: Study 3Health News:Flu Vaccine Does Protect Older People 2Health News:Flu Vaccine Does Protect Older People 3Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 3Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 2Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 3Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 4Health News:SCHIP Veto a Big Cavity for Children's Oral Healthcare, Advocates Say 2Health News:New York City's infant mortality rate declined in 2006 2Health News:New York City's infant mortality rate declined in 2006 3Health News:New York City's infant mortality rate declined in 2006 4
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
... The new Finnpipette Focus from ... to combine ergonomics with uncompromising ... handle plate offers a custom ... The new shorter tip cones ...
Inquire...
20L...
Medicine Products: